Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) have been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $8.00.
A number of analysts recently issued reports on the company. Guggenheim assumed coverage on Hims & Hers Health in a research report on Wednesday, April 13th. They issued a “buy” rating and a $10.00 price target for the company. Piper Sandler lowered their target price on shares of Hims & Hers Health from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, May 26th. Citigroup reduced their price objective on shares of Hims & Hers Health from $9.00 to $6.00 in a research report on Tuesday, May 10th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Hims & Hers Health in a research report on Thursday, March 10th. They set a “hold” rating and a $7.00 target price for the company.
Hims & Hers Health stock opened at $4.35 on Monday. The company’s 50-day moving average price is $4.13 and its 200-day moving average price is $4.86. The company has a market cap of $892.07 million, a PE ratio of -12.08 and a beta of 0.38. Hims & Hers Health has a twelve month low of $2.72 and a twelve month high of $11.81.
Hims & Hers Health (NYSE:HIMS – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $90.99 million. Hims & Hers Health had a negative return on equity of 22.41% and a negative net margin of 22.60%. The firm’s revenue for the quarter was up 93.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.14) earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health will post -0.35 earnings per share for the current year.
In other Hims & Hers Health news, Director Jules A. Maltz acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was bought at an average cost of $3.99 per share, with a total value of $199,500.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at $199,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jules A. Maltz bought 75,000 shares of the company’s stock in a transaction on Tuesday, June 14th. The shares were acquired at an average price of $3.66 per share, for a total transaction of $274,500.00. Following the completion of the acquisition, the director now owns 125,000 shares in the company, valued at $457,500. The disclosure for this purchase can be found here. Insiders own 43.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dark Forest Capital Management LP purchased a new position in Hims & Hers Health during the third quarter valued at approximately $32,000. Captrust Financial Advisors boosted its position in Hims & Hers Health by 1,827.4% during the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock valued at $36,000 after acquiring an additional 6,414 shares in the last quarter. Sciencast Management LP purchased a new position in shares of Hims & Hers Health in the 1st quarter valued at $53,000. Bradley Foster & Sargent Inc. CT purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth $65,000. Finally, NorthRock Partners LLC bought a new stake in Hims & Hers Health during the fourth quarter valued at about $67,000. Hedge funds and other institutional investors own 57.22% of the company’s stock.
Hims & Hers Health Company Profile (Get Rating)
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Featured Articles
Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
